Eli Lilly Reports Oral Weight-Loss Drug Helps Maintain Results After Switching from Injectables

Eli Lilly Says Orforglipron Helps Maintain Weight Loss After Switching From Injectable Incretins to Oral GLP-1 Therapy in Phase 3 Trial

Eli Lilly Submits Orforglipron for FDA Review for Obesity Treatment

Lilly's Orforglipron Helped People Maintain Weight Loss After Switching From Injectable Incretins to Oral Glp-1 Therapy in First-of-Its-Kind Phase 3 Trial

Eli Lilly: Participants Who Switched to Orforglipron From Wegovy Maintained All but 0.9 Kg of Previously Achieved Weight Loss on Average

Eli Lilly: Submitted Orforglipron to the U.S. FDA for Treatment of Obesity

Eli Lilly: Orforglipron Achieves Primary and Secondary Endpoints in Attain-Maintain Study

Eli Lilly: Overall Safety, Tolerability Profile of Orforglipron in Attain-Maintain Consistent With Previous Orforglipron Phase 3 Studies

BRIEF-Eli Lilly Cuts Price Of Popular Diabetes And Weight-Loss Drugs In Canada- Globe And Mail

Eli Lilly & Co. Cuts Price of Popular Diabetes and Weight-Loss Drugs in Canada -Globe and Mail

Eli Lilly Said Canadian List Price of Four-Week Supply of Mounjaro or Zepbound Would Be Lowered to $300 for 2.5 Milligram and 5 Milligram Dosages - Globe and Mail

AstraZeneca PLC ADR Falls Wednesday, Still Outperforms Market

EXCLUSIVE-US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers

Bristol Myers Squibb Co. Stock Underperforms Wednesday When Compared To Competitors

Exclusive-FDA Expects Respective April and October/November Submission Dates for Enlicitide and Sac-TMT

Exclusive-Merck's Cholesterol Pill Enlicitide and Cancer Therapy Sac-TMT Tapped for Program -Internal Documents

Exclusive-U.S. FDA Moving to Fast-Track Reviews of Two Merck Drugs Under Commissioner National Priority Voucher Pilot Program -Internal Documents

Correction to Lilly Drug Trial Article on Dec. 11